Develops tumor specific oncolytic viruses and patient specific cancer vaccines
Nouscom has raised €54M across 2 funding rounds from 4 investors, most recently a Series B round in Nov 2017. Based in Basel, Switzerland; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2017-11-07 | Series B | €42M | 5AM Ventures,Abingworth,LSP,Versant Ventures | View deal → |
| 2016-05-01 | Series A | €12M | LSP,Versant Ventures | View deal → |
